Growth - Gerresheimer AG

Gerresheimer is a profitable sustainable growth company

The implementation of the formula g strategy process was again an important driver of Gerresheimer's growth in the financial year. With strong customer orientation, innovation and a focus on the highest quality, our company has again grown profitably – despite market headwinds.

Injectables dominate the global drug pipeline. Injectables are also the most widely used route of administration for biologics. They account for around 90% of the global drug pipeline. The biologics market is growing significantly faster than the overall market. We expect average annual growth of more than 15% in the submarkets in which we operate.

Our broad product portfolio enables us to address global megatrends and win orders for new innovative drugs, in particular biologics such as drugs based on the peptide hormone GLP-1 (glucagon-like peptide 1) for the treatment of obesity.

GLP-1 is an example of the large market potential for biologic drugs. This high market potential offers us the opportunity to continue to grow profitably in the future.

System- and Solution Provider

As a system and solution provider and partner of choice for the global pharma and biotech industry, we support our customers in improving the quality of life and health of millions of patients worldwide. Gerresheimer offers one of the broadest, if not the broadest, portfolio of containment solutions and drug delivery systems on the market.

We combine products, technologies, and services to create custom drug therapy solutions to improve patients’ lives.

The product portfolio is divided across three core segments:

Containment Solutions — We safely package drugs for delivery to patients
Drug Delivery Systems — We ensure that drugs can be administered safely with precise dosing
Digital Therapy Support — We facilitate an optimized therapy process and an improved patient experience

Gerresheimer has a wealth of experience and expertise, meets the highest pharmaceutical quality standards, and has the ability to scale up the production of innovative systems and solutions worldwide to industrial levels.

This puts Gerresheimer in a position to master any challenge. We help our customers to bring every kind of drug, including highly innovative biologics, to and into the patient. We are constantly expanding our portfolio of high-quality, innovative products and solutions.

Strategic Investments

We are investing in key growth markets and continued our investment program in the 2024 financial year. With a particular focus on syringes, pens and autoinjectors, we have further expanded our capacities worldwide: For example, in Peachtree City and Morganton, USA, for pens, auto-injectors or high-quality containment solutions. We are also expanding our capacities in Queretaro, Mexico, Skopje, North Macedonia and Horsovsky Tyn, Czech Republic, for glass syringes, among other things. Our growth investments are an important driver of our margin expansion. The change in the product mix towards a higher proportion of high-quality solutions and, in particular, solutions for biologics will drive profitable growth in the coming years. The investments made in recent years are already paying off today.

Our syringe segment offers a wide range of innovative solutions, such as silicone-free systems, dual-chamber syringes and the InnoSafe solution. With the doubling of our syringe capacities, we expect to triple our sales in this area over the next few years.

We see high growth potential for ready-to-fill injection vials and cartridges in line with the successful market development for syringes. Over the past two decades, 95% of the market has shifted from non-pre-washed and non-sterilized syringes (‘bulk syringes’) to ready-to-fill syringes. We are also driving to replicate this success story for injection vials and cartridges, for example with EZ-fill Smart, the new industry standard for pre-sterilized ready-to-use (RTU) packaging.

Biologics and Medical Devices

Our expertise and strong track record are continuously increasing the share of sales accounted for by containment solutions and drug delivery systems for injectable biologics. Our ready-to-fill syringes, injection vials and cartridges in particular are influencing this positive development. Medical devices such as autoinjectors and pens are also supporting our growth. We are excellently positioned on the market in this area and work together with leading global pharmaceutical companies.

With our systems and solutions, we address the needs of our customers in the most important therapeutic areas - from chronic and autoimmune diseases, cell and gene therapy, vaccines and infectious diseases, ophthalmology, oncology, respiratory and cardiovascular diseases to diabetes and/or metabolic diseases. In all these therapeutic areas, we have the products, systems and solutions as well as the skills and expertise to be the right partner for pharmaceutical and biotech companies of all sizes and in every phase of the drug life cycle.